Related Experiment Video

Updated: Aug 7, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Cytochrome P450 (CYP) mutants and substrate-specificity alterations: segment-directed mutagenesis applied to human

P Urban1, A S Jobert, R Lainé

  • 1Centre de Génétique Moléculaire, Centre National de la Recherche Scientifique, UPR 2137, Avenue de la terrasse, 91190 Gif-sur-Yvette, France. urban@cgm.cnrs-gif.fr

Biochemical Society Transactions
|May 18, 2001
PubMed

Insights

This study engineered mutant forms of Cytochrome P450 (CYP) 1A1 enzymes using segment-directed mutagenesis to explore substrate specificity. The research identified specific amino acid combinations influencing how CYP1A1 interacts with various aromatic hydrocarbons.

Area of Science:

  • Biochemistry
  • Enzymology
  • Molecular Biology

Background:

  • Cytochrome P450 (CYP) enzymes are crucial for metabolizing diverse substrates, including procarcinogens.
  • The CYP1A subfamily, particularly CYP1A1, plays a significant role in the activation of procarcinogens.
  • Understanding CYP substrate specificity is vital for drug development and toxicology.

Purpose of the Study:

  • To investigate the role of a specific amino acid region (residues 204-214) in human CYP1A1's substrate specificity.
  • To generate and characterize a library of CYP1A1 mutants with combinatorial alterations in this key region.
  • To identify amino acid combinations that modulate CYP1A1 activity and substrate selectivity.

Main Methods:

  • Segment-directed mutagenesis was employed to create random combinatorial mutants of human CYP1A1 within amino acids 204-214.
  • Mutant CYP1A1 enzymes were expressed in an engineered Saccharomyces cerevisiae strain optimized for CYP activity.
  • Functional mutants were screened for altered activity and substrate specificity using various aromatic hydrocarbons.

Main Results:

  • A library of functional CYP1A1 mutants with combinatorial amino acid substitutions was successfully generated.
  • Mutant analysis revealed specific amino acid combinations within the targeted region that alter substrate specificity.
  • The study identified a putative loop region (amino acids 204-214) as critical for substrate selectivity, despite not being a canonical substrate-recognition site.

Conclusions:

  • The targeted region (amino acids 204-214) of CYP1A1 is a key determinant of its substrate specificity.
  • Combinatorial mutagenesis provides a powerful approach to dissecting enzyme-substrate interactions without prior assumptions.
  • These findings contribute to a deeper understanding of CYP enzyme function and can inform future drug design and toxicological assessments.

More Related Videos

Site-Directed Mutagenesis for In Vitro and In Vivo Experiments Exemplified with RNA Interactions in Escherichia Coli07:04

Site-Directed Mutagenesis for In Vitro and In Vivo Experiments Exemplified with RNA Interactions in Escherichia Coli

Published on: February 5, 2019

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...